{
  "thread": {
    "uuid": "d2efb29e5961b37a9dc4f1a35ec1741aeb1fc6ee",
    "url": "https://finance.sina.com.cn/stock/aigc/ywsygs/2025-09-04/doc-infphyzr8855056.shtml",
    "site_full": "finance.sina.com.cn",
    "site": "sina.com.cn",
    "site_section": "https://finance.sina.cn",
    "site_categories": [
      "tech",
      "top_news_hk",
      "top_news_sg",
      "top_news_tw",
      "top_news"
    ],
    "section_title": "新浪财经_金融信息服务商",
    "site_title": null,
    "title": "扬厉医药VB19055片启动Ⅰ期临床 适应症为高血压|高血压_新浪财经_新浪网",
    "title_full": "扬厉医药VB19055片启动Ⅰ期临床 适应症为高血压|高血压_新浪财经_新浪网",
    "published": "2025-09-04T07:31:00.000+03:00",
    "replies_count": 0,
    "participants_count": 1,
    "site_type": "news",
    "country": "CN",
    "main_image": "",
    "performance_score": 0,
    "domain_rank": 236,
    "domain_rank_updated": "2025-06-03T00:00:00.000+03:00",
    "licensing_agency": [],
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "d2efb29e5961b37a9dc4f1a35ec1741aeb1fc6ee",
  "url": "https://finance.sina.com.cn/stock/aigc/ywsygs/2025-09-04/doc-infphyzr8855056.shtml",
  "ord_in_thread": 0,
  "author": "小浪财讯",
  "published": "2025-09-04T07:31:00.000+03:00",
  "title": "扬厉医药VB19055片启动Ⅰ期临床 适应症为高血压|高血压_新浪财经_新浪网",
  "text": "药物临床试验登记与信息公示平台数据显示，浙江扬厉医药技术有限公司的评价VB19055片在中国健康成人受试者中的安全性、耐受性、药代动力学特征、食物影响和QT/QTc研究的随机、双盲、安慰剂对照I期临床研究已启动。临床试验登记号为CTR20253416，首次公示信息日期为2025年9月4日。\n该药物剂型为片剂，用法为口服，有0.1mg、0.5mg、1mg三种规格，用法用量包括2片/日、6片/日、12片/日等，用药时程有单次给药和连续给药10天。本次试验主要目的为评估单、多次口服VB19055片在健康受试者中的安全性和耐受性；次要目的包括评估药代动力学特征、评价食物对PK特征的影响、评估药效学特征等；探索性目的为初步评估对QT/QTc间期的影响和探索代谢产物。\nVB19055片为化学药物，适应症为高血压（包括难治性高血压在内的未控制高血压）。高血压指体循环动脉血压增高，收缩压≥140mmHg和（或）舒张压≥90mmHg，常见症状有头晕、头痛等，通过血压计测量诊断。\n本次试验主要终点指标包括安全性和耐受性终点（不良事件、实验室检查、12导联心电图、体格检查、生命体征等）；次要终点指标包括PK指标、主要血PD指标、主要尿PD指标、其他PD指标、探索性终点（Fridericia法校正的QTc间期相对于安慰剂的变化等）。\n目前，该实验状态为进行中（尚未招募）。\n风险提示：市场有风险，投资需谨慎。本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验，因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联系biz@staff.sina.com.cn。",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "chinese",
  "sentiment": "positive",
  "categories": [
    "Health",
    "Economy, Business and Finance",
    "Social Issue"
  ],
  "topics": [
    "Health->health treatment and procedure",
    "Health->drug rehabilitation",
    "Health->medical test",
    "Economy, Business and Finance->products and services",
    "Economy, Business and Finance->healthcare industry"
  ],
  "ai_allow": true,
  "has_canonical": false,
  "breaking": true,
  "webz_reporter": false,
  "external_links": [],
  "external_images": [],
  "internal_images": [],
  "entities": {
    "persons": [],
    "locations": [],
    "organizations": []
  },
  "syndication": {
    "syndicated": null,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": {
    "categories": [],
    "top_news": [
      "top_news_hk",
      "top_news_sg",
      "top_news_tw",
      "top_news"
    ],
    "bias": null,
    "source": {
      "type": null,
      "city": null,
      "state": null,
      "country": null,
      "domain_type": null,
      "agency": null,
      "organization_name": null
    }
  },
  "rating": null,
  "crawled": "2025-09-04T07:38:09.664+03:00",
  "updated": "2025-09-05T08:05:29.000+03:00"
}